Image 2_Case report: Toripalimab plus anlotinib in postoperative recurrent renal pelvic sarcomatoid urothelial carcinoma.tif

Image 2_Case report: Toripalimab plus anlotinib in postoperative recurrent renal pelvic sarcomatoid urothelial carcinoma.tif

Background<p>Sarcomatoid urothelial carcinoma (SUC) is a rare renal malignancy. Its biological malignancy is high, the prognosis is poor, diagnostic and treatment options are few, and there is no standard treatment plan.</p>Case presentation<p>In this case, a 64-year-old woman was...

Full description

Saved in:
Bibliographic Details
Main Author: Xinrong Hu (14605106) (author)
Other Authors: Lin Deng (127858) (author), Yufei Pan (9342095) (author), Guozhen Zhang (1708621) (author), Xiaolan Ruan (8334120) (author), Xinlan Jiang (19735681) (author), Hao Shen (195461) (author), Lei Zhao (144153) (author), Jun Dong (43792) (author)
Published: 2024
Subjects:
Oncology and Carcinogenesis not elsewhere classified
toripalimab
anlotinib
postoperative recurrence
renal pelvic urothelial carcinoma
upper-tract urothelial carcinoma
sarcomatoid urothelial carcinoma
immune checkpoint inhibitor
tyrosine kinase inhibitor
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items